Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, PR China; Department of Endocrinology of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, PR China.
J Control Release. 2022 Jul;347:14-26. doi: 10.1016/j.jconrel.2022.04.038. Epub 2022 May 4.
The accumulation of nanomedicines in tumor tissues determines their therapeutic efficacy. We herein exploit the tropism of macrophages to improve the accumulation and retention time of nanomedicine at tumors. Interestingly, macrophages are not merely as transporters, but killers activated by nanomedicine. The system(M@C-HA/ICG) was established by decorating macrophages with hyaluronic acid-modified hollow mesoporous carbon (C) nanoparticles loading indocyanine green (ICG). Notably, C nanoparticles with superior photothermal conversion capability not merely guarantee the efficient delivery of ICG through high drug loading efficiency and inhibiting the premature leaky, but effectually activate the polarization of macrophages. The results exhibited that those activated macrophages could release pro-inflammatory cytokines (NO, TNF-α, IL-12), while M@C-HA/ICG afforded about 2-fold higher tumor accumulation compared with pure nanoparticle C-HA/ICG and produced heat and singlet oxygen (O) under irradiation of an 808 nm laser, realizing the combination of photodynamic therapy (PDT), photothermal therapy (PTT) and cytokines-mediated immunotherapy. Specially, we also investigated the relationship of singlet oxygen (O) or temperature and tumor-killing activity for understanding the specific effectual procedure of PDT/PTT synergistic therapy. Overall, we firstly established an "all active" delivery system integrating the features of nanomedicine with biological functions of macrophages, providing a novel insight for cell-mediated delivery platform and tumor targeted multimodality anti-cancer therapy.
纳米药物在肿瘤组织中的积累决定了其治疗效果。我们利用巨噬细胞的趋向性来提高纳米药物在肿瘤部位的积累和保留时间。有趣的是,巨噬细胞不仅是载体,还是被纳米药物激活的杀伤细胞。该系统(M@C-HA/ICG)是通过用透明质酸修饰的中空介孔碳(C)纳米粒子负载吲哚菁绿(ICG)来修饰巨噬细胞而建立的。值得注意的是,具有优异光热转换能力的 C 纳米粒子不仅通过高载药效率和抑制过早泄漏来保证 ICG 的有效传递,而且还能有效地激活巨噬细胞的极化。结果表明,这些被激活的巨噬细胞可以释放促炎细胞因子(NO、TNF-α、IL-12),而 M@C-HA/ICG 与纯纳米粒子 C-HA/ICG 相比,肿瘤积累增加了约 2 倍,并在 808nm 激光照射下产生热量和单线态氧(O),实现了光动力治疗(PDT)、光热治疗(PTT)和细胞因子介导的免疫治疗的联合。特别地,我们还研究了单线态氧(O)或温度与肿瘤杀伤活性的关系,以了解 PDT/PTT 协同治疗的具体有效过程。总的来说,我们首次建立了一个“全活性”的递药系统,将纳米药物的特性与巨噬细胞的生物学功能相结合,为细胞介导的递药平台和肿瘤靶向多模态抗癌治疗提供了新的见解。